Reading Pipeline By Evidence Instead Of Coverage Produces A Forecast Leaders Can Trust

Every sales leader knows the comfort of a healthy coverage ratio: three, four, five times the target sitting in the pipeline, apparently more than enough to make the quarter. The trouble is that the ratio is a volume measurement wearing the costume of a forecast. It counts how much opportunity exists without saying anything about whether that opportunity is real, and two teams carrying identical coverage can be in completely different shape depending on what sits underneath the number. Treating coverage as evidence of future revenue, rather than as a measure of raw capacity, is how forecasts detach from reality, and fixing it starts with interrogating what the pipeline is actually made of.

Kate Futch is a Global Sales Leader with a 25-year background in life sciences, most recently serving as Senior Vice President and Head of Global Sales at ProductLife Group. She's spent much of her career examining the operating behavior beneath pipeline numbers rather than taking the numbers at face value, and argues that the distinction between capacity and confidence is where most forecasting goes wrong.

“Coverage tells me whether we have enough opportunity in the pipeline. It doesn’t tell me whether we have enough evidence to believe the number,” Futch says. That gap between opportunity and evidence is where her approach to pipeline health begins.

Coverage is a capacity metric

The core error, in Futch’s view, is a category mistake. “Coverage should be looked at more as a capacity metric and not just automatically as a confidence metric,” she says. It can confirm that enough potential revenue exists to support the target, which is useful, but it slides into dangerous territory the moment it gets treated as actual evidence of future performance.

While leading global sales at ProductLife Group, Futch worked to the same three-to-five-times coverage ratio most organizations target, but she's wary of the false security it can breed. The problem is what the ratio assumes. “Every dollar in that pipeline is essentially being treated as though it carries comparable probability,” she says, when in reality a newly qualified opportunity with a compelling business problem, executive sponsorship, and clear next steps is nothing like one that's been sitting in the pipe for six months.

Identical coverage, completely different health

Because the ratio flattens those differences, the same number can describe opposite realities. Futch points out that two reps, or two whole teams, can enter a quarter at the same coverage, say four times target, built from entirely different material. One version consists of opportunities with confirmed customer priorities, multiple stakeholder relationships, an understood procurement process, and documented commitments advancing the deal. The other, at the same ratio, is aging opportunities bled over from prior quarters, single-threaded relationships, unverified budgets, and close dates the salesperson essentially invented to manufacture the appearance of coverage. The number is identical; the health is not.

This is also why she treats coverage as fundamentally backward-looking. “It’s reflecting what the sales team have entered into the CRM and how those opportunities have been staged,” she points out, which means weak qualification standards or a reluctance to purge dead deals actually inflate the ratio even as real health declines, an inverse relationship that rewards exactly the wrong behavior.

Watch the bleed-over, and the clock

One of the clearest health signals, Futch believes, is the bleed-over effect. The tell is opportunities “continuously being pushed from one quarter to the next, so they’re looking similar or almost identical, but they’re nowhere close in terms of realizing that revenue,” she says. That pattern exposes deals with the appearance of pipeline but none of the movement, and it tends to hide behind the flashier top-line number. Part of what sustains it is unverified close dates. Often, Futch says, “the salesperson is generating those close dates arbitrarily just to make it appear as though they have the coverage needed for that quarter,” with no customer evidence behind them.

Timing compounds the issue, because coverage says nothing about when revenue will actually land. A rep can hold enough pipeline for the quarter while half of it won't reach a buying decision until much later. Even a closed deal carries a lag. “Depending on the terms of the contracting, maybe you’re not realizing revenue for 45 days once it’s closed, so you have to factor that into the health as well,” Futch explains. Accounting for velocity, how deals distribute across the time horizon, and recognition timing is what separates coverage that can convert in the near term from a number that merely looks sufficient.

Internal activity doesn't mean buyer progress

The distinction Futch keeps returning to is between what the seller does and what the customer does. “Our internal activity is not the same as buyer progress,” she says, describing this as “critical to keep in mind.” A team can run meetings, send proposals, schedule demos, and dutifully update the CRM every day, but if the customer’s buying process is stationary, none of that motion is advancing the deal.

The healthier signal is whether the customer is taking action between conversations. “Are they leaving each meeting and engagement where they’re actually doing something, and they’re coming back to us with the results of those actions?” This is the question that separates a real opportunity from a stalled one dressed up in seller activity. When buyer movement is absent, the disconnect surfaces later as the quarter-to-quarter bleed-over that erodes a pipeline’s credibility.

Make the evidence show up in the system

Operationalizing that distinction is the hard part, and Futch is clear that the answer isn't simply a better dashboard. The information going in has to be robust in the first place. “It’s almost like the AI conversation these days,” she says. “If what you’re putting in is not robust evidence-based information, then what you’re going to get back out is not going to improve your results.”

She presses for daily CRM updates, not as busywork but so that nothing falls through the cracks and so multiple people working a large opportunity share one consolidated view of the key takeaways. That shared record prevents the rework and divergence that happens when different parts of an organization pursue the same deal down different paths, and it shows the customer a cohesive team rather than a set of disconnected contacts. The stages themselves, she argues, should reflect where customer commitment actually is, not merely that a rep completed an action, so that leaders can assess health through a narrow set of questions: what is the evidence, what kind of movement exists, and where is the risk.

You get the pipeline you ask for

Futch’s closing point reframes the problem as a leadership one. In her experience, sales organizations largely produce whatever their leaders request, or what teams think their leaders request. “If you’re asking primarily for volume, that’s what you’ll get back,” she says.

The alternative is to ask for something harder and more specific, and to define it clearly enough that reps have no ambiguity about the standard. “You need to ask for the evidence, customer movement, and discipline qualification, and help define that for your teams.” Do that, and the pipeline starts to consist of deals backed by real buyer commitment rather than optimistic close dates. Ask only for coverage, and coverage is exactly what you'll get, whether or not it ever becomes revenue.